Glaucoma is the leading cause of irreversible blindness worldwide, and the second most common cause in Australia. Current treatments for glaucoma, including medication and surgery, often cause side effects and give unpredictable results.
VividWhite has developed a micro sized device that is surgically implanted in the eye to reduce intraocular pressure (IOP) and treat glaucoma. The VividWhite glaucoma implant (VW51) is currently being used in a 10-participant clinical study with favourable safety and efficacy results and a significant reduction in post-operative care.
This project will support the Australian manufacturing of the VividWhite glaucoma implant for use in an Australian multi-centre pivotal clinical study, to generate data for registration with the regulatory authorities to allow commercialisation in Australia, Europe and the USA.
CTCM Project Round: Two
State: Victoria
Project Partner:
Funding:
Duration: July 2023 – June 2025
